Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
NCT02130362 · View on ClinicalTrials.gov ↗
Study Summary
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in pediatric patients with moderately to severely active CD who are treated as recommended in the local product label.
Conditions Studied
Study Locations (20)
California
- Children's Hospital Los Angeles /ID# 141551 — Los Angeles
- Private practice: Dr. Shervin Rabizadeh /ID# 137269 — Los Angeles
- Rady Children's Hospital San Diego /ID# 140883 — San Diego
- Univ California, San Francisco /ID# 141312 — San Francisco
Massachusetts
- Tufts Medical Center /ID# 143581 — Boston
- Massachusetts General Hospital /ID# 141552 — Boston
- Boston Children's Hospital /ID# 164102 — Boston
- Duplicate_UMass Chan Medical School /ID# 148325 — Worcester
Alabama
- Univ Alabama, Birmingham CCC /ID# 146060 — Birmingham
- University of South Alabama /ID# 137255 — Mobile
Connecticut
- Connecticut Children's Medical Center - Hartford /ID# 137265 — Hartford
- Yale University School of Medicine /ID# 137257 — New Haven
Florida
- Nemours Children's Health System /ID# 148498 — Jacksonville
- University of Miami /ID# 140893 — Miami
Georgia
- Winship Cancer Institute of Emory University /ID# 144274 — Atlanta
- Children's Ctr Digestive, US /ID# 144625 — Atlanta
Arizona
- Phoenix Children's Hospital /ID# 141336 — Phoenix
Colorado
- Children's Hospital Colorado - Aurora /ID# 137261 — Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,446 participants |
| Start Date | 2014-08-28 |
| Est. Completion | 2030-11 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02130362
The ClinicalTrials.gov registry entry for NCT02130362 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,446 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 603 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02130362 reports 20 study locations spanning 10 distinct geographic areas — top geographies include California, Massachusetts, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02130362 about?
NCT02130362 is a clinical study titled "A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)". This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in pediatric patients with moderately to severely active CD who are treated as recommended in the local product label.
What is the current status of trial NCT02130362?
This trial is currently active not recruiting. The enrollment target is 1,446 participants. The study started on 2014-08-28. Estimated completion is 2030-11.
What conditions does trial NCT02130362 study?
This clinical trial studies the following conditions: Crohn's Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT02130362?
This trial is sponsored by AbbVie, which has 603 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02130362 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.